WO2012033162A1 - 毛成長制御方法、毛成長制御剤の評価又は選択方法、及び毛成長抑制剤 - Google Patents
毛成長制御方法、毛成長制御剤の評価又は選択方法、及び毛成長抑制剤 Download PDFInfo
- Publication number
- WO2012033162A1 WO2012033162A1 PCT/JP2011/070481 JP2011070481W WO2012033162A1 WO 2012033162 A1 WO2012033162 A1 WO 2012033162A1 JP 2011070481 W JP2011070481 W JP 2011070481W WO 2012033162 A1 WO2012033162 A1 WO 2012033162A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dnajc6
- hair growth
- extract
- protein
- test substance
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/27—Asclepiadaceae (Milkweed family), e.g. hoya
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
- A61Q7/02—Preparations for inhibiting or slowing hair growth
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
Definitions
- the present invention relates to a hair growth control method, a hair growth control agent evaluation or selection method, and a hair growth inhibitor.
- Biological hair and body hair protect biologically important organs such as the head, chest and limbs.
- hair on limbs and the like is preferably not in terms of aesthetic appearance.
- Examples of the method for removing body hair include a mechanical removal method using a shaver, a hair removal device, and the like, and a removal method by chemical action using a hair removal agent or a hair removal agent.
- these hair removal methods may be accompanied by physical or chemical irritation to the skin and are still insufficient in terms of hair suppression action, so that the hair removal treatment is performed again after a certain period of time. There must be. Reduction of body hair removal processing is desired.
- Patent Documents 1 to 3 Conventionally, when evaluating or selecting a hair restorer or a hair suppressant, it is applied to the skin of a living body (Patent Documents 1 to 3), or in vitro, human, mouse or rat, or pig hair follicle organ After the candidate substance was administered to the culture, the degree of hair elongation and hair follicle growth was measured, and the hair growth or hair-loss action of the candidate substance was evaluated based on the measurement results (Patent Documents 4 to 7, Non-patent documents 1 to 3). Considering the efficiency and accuracy of evaluation, in vitro testing is more preferable.
- organ culture of hair follicles in vitro may be difficult to obtain sample hair follicles, it takes time to cultivate, and several days before hair growth and hair follicle growth are observed. Therefore, there is a problem that it takes time to evaluate.
- an in vitro screening system for evaluating or selecting hair restorers or hair suppressants more efficiently.
- Patent Document 7 observes that heat shock proteins HSP-27, HSP-70 and HSP-90 are present in human hair follicles, and that hair fiber growth is significantly reduced by administration of HSP-27 antibody to hair follicles. It has been described that the growth of human hair follicles was reduced in a dose-dependent manner by the administration of HSP-90 specific inhibitor geldanamycin or HSP synthesis inhibitor KNK437. However, since there are many types of heat shock proteins and their functions are diverse, the molecular mechanism by which the above heat shock proteins are involved in hair growth is not clear, and whether other heat shock proteins can be involved in hair growth. Can not be predicted.
- Funabarasou (Cynanchum atratum) is a perennial plant of the Asclepiadaceae vincetoxicum, the root has been used for Kampo agent such as Shirozenmaiyu.
- Funabara Sou is known to have medicinal effects such as cool fever, antipyretic, diuretic action and the like, and as its medicinal ingredient, Cynanchol having a cardiac glycoside action is known.
- Patent Document 8 discloses a herbal extract for skin growth containing a herbal extract containing white rose and a herbal extract having an lyostatic action, an active ingredient thereof, a herbal extract having an angiogenic activity and an active ingredient thereof.
- Patent Document 9 describes the use of a composition containing an extract of a plant belonging to the genus Calyceae for cosmetic treatment of human skin including inhibition, suppression or delay of hair growth. However, it was not clear what the effect of beech roses alone on hair growth.
- the present invention provides a hair growth control method comprising the step of controlling the activation level of DnaJC6 in hair tissue.
- the present invention provides the following steps (A) to (C): (A) a step of measuring the expression level of DnaJC6 in cells capable of expressing DnaJC6 in the presence and absence of a test substance; (B) comparing the expression level of DnaJC6 in the cell in the presence of the test substance with the expression level of DnaJC6 in the cell in the absence of the test substance; and (C) in the presence and absence of the test substance.
- a method for evaluating or selecting a hair growth regulator comprising: Yet another aspect of the present invention is beech grass or an extract thereof for use in hair growth inhibition. Alternatively, it is the use of beech grass or an extract thereof in the manufacture of a medicament or cosmetic for suppressing hair growth. In yet another aspect, the present invention provides a method for inhibiting hair growth comprising applying beech grass or an extract thereof to skin tissue where hair growth inhibition is desired. In another aspect, the present invention provides a hair growth inhibitor containing beech grass or an extract thereof as an active ingredient.
- non-therapeutic is a concept that does not include a medical act, that is, a treatment act on the human body by treatment.
- hair growth control means an action of promoting or suppressing the growth of hair or hair follicle, or an action of increasing or decreasing hair diameter. That is, “hair growth control” in the present specification is a concept including promotion and suppression of hair growth.
- DnaJC6 is a protein classified as a heat shock protein. There are many families of heat shock proteins, for example, broadly divided into HSP110, HSP90, HSP70, HSP60, HSP40, HSP27, and HSP10 families. Among these, DnaJC6 is a molecular chaperone belonging to the DNAJ / HSP40 family.
- DnaJC6 gene refers to a promoter that controls a gene encoding DnaJC6, its mRNA, and a gene encoding DnaJC6, respectively.
- the present invention relates to a hair growth control method by controlling gene expression, a method for evaluating or selecting a hair growth control agent using gene expression as an index, and a hair growth inhibitor.
- the present inventors can control hair growth by controlling the expression of DnaJC6, can efficiently evaluate or select a substance that controls hair growth by using the expression of DnaJC6 as an index, and hair growth. As a result of searching for a substance that suppresses hair, it was found that beech grass or its extract has an action of suppressing hair growth.
- hair growth can be controlled at a desired part of the animal body. Further, according to the present invention, it is possible to evaluate or select a hair growth control agent in vitro simply, quickly and efficiently. Moreover, according to this invention, hair growth suppression can be implement
- the present invention provides a hair growth control method comprising the step of controlling the activation level of DnaJC6 in hair follicle tissue.
- tissue examples include animal living tissue and animal living tissue.
- the animal is preferably a human or non-human mammal, more preferably a human.
- the animal includes animals that require hair growth control, for example, animals that desire or do not desire hair growth or hair growth, animals that desire hair removal or hair removal, animals that do not desire hair removal, and the like.
- tissues derived from living bodies include tissues collected from animals and cultures thereof.
- the activation level is controlled by, for example, the abundance of the DnaJC6 protein in the tissue, the activation of the DnaJC6 protein, the expression of the DnaJC6 protein, the expression of the gene or mRNA encoding the DnaJC6 protein, or the promoter of the gene encoding the DnaJC6 protein. Can be achieved by controlling the activation of. These may be controlled independently or in combination.
- the controlling step may be a step of suppressing hair growth by reducing the activation level of DnaJC6.
- Means for reducing the activation level of DnaJC6 include, for example, inactivation of DnaJC6 protein using an antibody specific for DnaJC6 protein, transcription of DnaJC6 gene to mRNA by inhibiting the activity of DnaJC6 gene promoter. Examples thereof include suppression, suppression of translation from DnaJC6 mRNA to protein by means such as RNAi.
- the activation level is preferably reduced by 20% or more, more preferably 50% or more, as the activity of the promoter of the DnaJC6 gene.
- the expression level of DnaJC6 mRNA is preferably decreased by 10% or more, more preferably 20% or more. The decrease in the activation level of DnaJC6 suppresses the hair growth of the tissue.
- the controlling step may be a step of promoting hair growth by enhancing the activation level of DnaJC6.
- means for enhancing the activation level of DnaJC6 include introduction of the DnaJC6 gene into cells of the tissue, introduction of an expression vector containing the DnaJC6 gene into cells of the tissue, and increase of the activity of the promoter of the DnaJC6 gene. Include promotion of transcription from the DnaJC6 gene to mRNA, suppression of degradation of DnaJC6 mRNA, suppression of degradation of DnaJC6 protein, and the like.
- the activation level is preferably increased by 20% or more, more preferably 50% or more as the activity of the promoter of the DnaJC6 gene.
- the expression level of DnaJC6 mRNA is preferably increased by 10% or more, more preferably 20% or more.
- a method for evaluating or selecting a hair growth regulator comprising the following steps (A) to (C) is provided: (A) a step of measuring the expression level of DnaJC6 in cells capable of expressing DnaJC6 in the presence and absence of a test substance; (B) comparing the expression level of DnaJC6 in the cell in the presence of the test substance with the expression level of DnaJC6 in the cell in the absence of the test substance; and (C) in the presence and absence of the test substance.
- Examples of the “cell capable of expressing DnaJC6” include a cell having a DnaJC6 gene inherently and capable of expressing it, and a cell introduced exogenously to express the DnaJC6 gene.
- the cell may be a cell collected from a living body, a cell contained in a tissue or organ collected from a living body, or a cultured cell.
- the cell is derived from a mammal.
- Examples of cells that naturally have the DnaJC6 gene and are capable of expressing it include cells derived from any tissue of the living body, but preferably cells derived from skin collected from mammals such as mammals.
- Cells that have been able to express the DnaJC6 gene exogenously can be obtained by introducing an expression vector incorporating the DnaJC6 gene into any mammalian cell and transforming the cell. Methods for producing an expression vector incorporating the DnaJC6 gene and methods for introducing the expression vector into mammalian cells are well known to those skilled in the art.
- test substance is not particularly limited as long as it is a substance desired to be used as a hair growth control agent.
- the expression level of DnaJC6 in cells capable of expressing DnaJC6 is measured in the presence and absence of the test substance.
- the expression level of DnaJC6 is measured before and after administration of a test substance to cells, in a test substance addition group and a test substance non-addition group, or in a test substance addition group and a control substance addition group, respectively.
- the measurement of the expression level of DnaJC6 can be carried out using as an index the expression of DnaJC6 protein, the expression of a gene or mRNA encoding DnaJC6 protein, the amount of activation of the promoter of the gene encoding DnaJC6 protein, or the like. These indicators may be measured alone or in combination.
- the measurement may be performed according to a method known in the art as a method for measuring a parameter used as an index (for example, protein expression, gene or mRNA expression, promoter activation, etc.).
- methods for measuring the expression level of a gene or mRNA encoding DnaJC6 protein include polymerase chain reaction (PCR) methods such as RT-PCR, Real-time RT-PCR, Northern blotting method, RNase protection assay method, DNA array Analysis and the like.
- PCR polymerase chain reaction
- a method for measuring the expression level of DnaJC6 protein agarose gel electrophoresis, SDS-PAGE, chromatography, immunoassay (for example, immunohistochemistry using an antibody specific for DnaJC6 protein, ELISA method, RIA method, Western blot method, immunoprecipitation, etc.), colorimetric determination method, fluorescence / optical measurement method, mass spectrometry, electron microscope observation, etc., and combinations thereof, but are not limited thereto.
- Western blotting method, ELISA method, or RIA method using an antibody specific for DnaJC6 protein is preferable.
- the value measured in the step (A) is compared between the case where the test substance is present and the case where it is absent. For example, before and after administration of the test substance, or by comparing the test substance addition group with the test substance non-addition group or the control substance addition group.
- the expression of DnaJC6 protein measured in (A) the expression of a gene or mRNA encoding DnaJC6 protein, the amount of activation of the promoter of the gene encoding DnaJC6 protein, etc. before and after administration of the test substance Comparison is made between the added group and the test substance non-added group, or between the test substance added group and the control substance added group. Preferably, the comparison is made statistically.
- the hair growth control effect of the test substance is evaluated based on the comparison result obtained in the above (B).
- a substance that has affected the expression of DnaJC6 can be selected as a hair growth regulator.
- the test substance can be selected as a hair growth regulator.
- a test substance that decreases the expression level of DnaJC6 is selected as a hair growth inhibitor.
- the substance is a hair growth inhibitor. Selected as. It is preferable that the decrease in the expression level is statistically significant.
- a test substance that increases the expression level of DnaJC6 is selected as a hair growth promoter.
- the expression level of DnaJC6 mRNA in the presence of the test substance is preferably increased by 10% or more, more preferably by 20% or more compared to the case in the absence of the test substance, the substance is a hair growth promoter. Selected as. It is preferable that the decrease in the expression level is statistically significant.
- a method including the following steps (a) to (d) can be mentioned as a preferred example: (A) introducing a reporter gene controlled by a promoter of a gene encoding DnaJC6 into a cell capable of expressing DnaJC6; (B) measuring the amount of the reporter gene expression product in the cell in the presence and absence of the test substance; (C) comparing the amount of the reporter gene expression product in the cell in the presence of the test substance with the amount of the reporter gene expression product in the cell in the absence of the test substance; and (d) the presence of the test substance A step of selecting the test substance as a hair growth regulator when the amount of the reporter gene expression product is significantly different between under and in the absence.
- the promoter used for the measurement is preferably the human DnaJC6 promoter.
- the human DnaJC6 promoter one to several (preferably 1 to 10, more preferably 1 to 5) promoters having the nucleotide sequence represented by SEQ ID NO: 1 and the nucleotide sequence represented by SEQ ID NO: 1. ) Are substituted, deleted, inserted, added, and controlled by a transcription factor similar to the promoter having the base sequence shown in SEQ ID NO: 1 to control the expression of downstream genes.
- a reporter gene controlled by the promoter of the gene encoding DnaJC6 is introduced into a cell capable of expressing DnaJC6.
- a reporter gene is operably linked downstream of the promoter.
- the reporter gene is selected from the group consisting of luciferase, chloramphenicol acetyltransferase, ⁇ -galactosidase, ⁇ -glucuronidase, and green fluorescent protein.
- the above (b) to (d) are the same as the above (A) to (C) except that the measurement target is the amount of the reporter gene expression product. That is, in (d) above, when the amount of the reporter gene expression product of the cells is significantly different between in the presence and absence of the test substance, the test substance is selected as a hair growth regulator. Can do.
- the test substance that decreases the amount of the reporter gene expression product can be selected as a hair growth inhibitor, and the test substance that increases the amount of the reporter gene expression product can be selected as a hair growth promoter.
- the decrease in the amount of reporter gene expression product in the presence of the test substance is preferably 20% or more, more preferably 50% or more compared to the absence of the test substance, the substance is a hair growth inhibitor. Selected as an agent.
- the increase in the amount of the reporter gene expression product in the presence of the test substance is preferably 20% or more, more preferably 50% or more, compared to the case where the test substance is absent, the substance is used for hair growth. Selected as an accelerator. It is preferable that the decrease in the expression level is statistically significant.
- the hair growth control agent thus obtained can be used for hair growth, hair growth, hair removal, hair removal, hair growth suppression, or the like, or hair growth agents, hair growth agents, hair removal agents, hair removal agents, hair growth inhibition. It can be an active ingredient such as an agent.
- the hair growth regulator by administering the hair growth regulator to a subject in need of promoting or suppressing hair growth such as hair growth, hair growth, hair removal, hair removal, hair growth inhibition, etc. Hair growth, hair growth, hair removal, hair removal, hair growth inhibition, etc. can be realized by promoting or suppressing.
- the hair growth regulator may be used as a composition for hair growth, hair growth, hair removal, hair removal, hair growth suppression, etc., as a medicine, quasi-drug, cosmetic or food and drink, or for their production. Can be used for
- beech grass extract has an effect of significantly suppressing the elongation of human organ cultured hair. Therefore, beech grass or its extract is useful as a hair growth inhibitor.
- beech rose or an extract thereof can exert effects such as suppression of hair growth or hair growth, hair removal, and hair removal through the hair growth suppressing action. That is, beech grass or an extract thereof can be used for hair growth inhibition, hair growth or hair growth inhibition, hair removal, hair removal, and the like.
- the use can be in humans or non-human animals, or specimens derived therefrom, and can be therapeutic or non-therapeutic.
- the present invention provides a hair growth inhibitor containing beech grass or an extract thereof as an active ingredient.
- the hair growth inhibitor of the present invention consists essentially of beech grass or its extract.
- the hair growth inhibitor can be used for hair growth or hair growth inhibition, or for hair removal or hair removal.
- “Funabarasou” refers to the perennial plant Cynanchum atratum belonging to the genus Gullaceae
- “Funabara extract” means an extract obtained from Amaranthus.
- the extract may be an extract from any part of beech grass, for example, whole grass or root, or a combination thereof, but an extract from root is preferred.
- the part may be subjected to the extraction step as it is, or may be subjected to the extraction step after being pulverized, cut or dried.
- the extract of beech roses according to the present invention is extracted by extracting the beech roses at room temperature (eg, 4 to 50 ° C.) or under heating (room temperature to solvent boiling point), or using an extraction device such as a Soxhlet extractor. Can be obtained.
- Either a polar solvent or a nonpolar solvent can be used as a solvent for extraction.
- the solvent include water; alcohols such as methanol, ethanol, propanol and butanol; polyhydric alcohols such as propylene glycol and butylene glycol; ketones such as acetone and methyl ethyl ketone; methyl acetate and ethyl acetate Esters; linear and cyclic ethers such as tetrahydrofuran and diethyl ether; polyethers such as polyethylene glycol; hydrocarbons such as squalane, hexane, cyclohexane and petroleum ether; aromatic hydrocarbons such as toluene; dichloromethane and chloroform And halogenated hydrocarbons such as dichloroethane; and supercritical carbon dioxide; pyridines; organic solvents such as oils and fats, other oils such as wax; and mixtures thereof.
- Preferable examples include water, alcohols and a
- the mixing ratio (volume ratio) of alcohols and water in the aqueous alcohol solution is preferably 0.001 to 100: 99.999 to 0, more preferably 5 to 95:95 to 5, and 20 to 80:80 to 20 Is more preferable, 30 to 70:70 to 30 is still more preferable, and 40 to 60:60 to 40 is still more preferable.
- the ethanol concentration is preferably 40 to 60% by volume.
- the amount of the solvent used is preferably 1 to 100 mL with respect to 1 g of beech root (dry mass conversion), and the extraction time is preferably 1 minute to 2 months, more preferably 10 minutes to 4 weeks.
- the extraction temperature at this time is 0 ° C. to the boiling point of the solvent, more preferably 10 to 60 ° C., and further preferably 15 to 40 ° C.
- the extraction means for obtaining the extract specifically, solid-liquid extraction, liquid-liquid extraction, immersion, decoction, leaching, reflux extraction, ultrasonic extraction, microwave extraction, stirring, and the like can be used.
- a preferred example of immersion is immersion at 15 to 40 ° C. for 1 hour to 4 weeks.
- solid-liquid extraction with stirring is desirable.
- suitable conditions for this solid-liquid extraction include stirring at 1000 to 5000 rpm under 10 to 100 ° C. (preferably 20 to 100 ° C.) for 1 to 30 minutes.
- a means for extracting under a so-called non-oxidizing atmosphere while removing dissolved oxygen by bubbling degassing or inert gas such as nitrogen gas may be used in combination.
- Beech grass or an extract thereof is a composition for hair growth inhibition, hair growth or hair growth inhibition, hair removal or hair removal, a pharmaceutical, a quasi-drug, a cosmetic, a food or drink, or a raw material thereof, or It can be used as feed or its raw material, or can be used for their production.
- the composition, medicine, quasi-drug, cosmetic, food and drink or raw material thereof, or feed or raw material thereof can be produced or used for human or non-human animals.
- beech grass or an extract thereof is a composition for suppressing hair growth, for suppressing hair growth or hair growth, or for hair removal or hair removal, a pharmaceutical, a quasi-drug, a cosmetic, a food or drink, a feed, Or it can mix
- the above-mentioned medicine or quasi-drug contains beech grass or an extract thereof as an active ingredient.
- the pharmaceutical or quasi drug can be administered in any dosage form.
- the administration form may be oral administration or parenteral administration such as external preparation.
- oral dosage forms include solid dosage forms such as tablets, coated tablets, granules, powders, capsules, and liquid dosage forms such as elixirol, syrups and suspensions, and parenteral dosage forms. Examples thereof include injection, infusion, transdermal, transmucosal, nasal, enteral, inhalation, suppository, bolus, and patch.
- the above-mentioned medicine and quasi-drug may contain beech grass or an extract thereof alone or in combination with a pharmaceutically acceptable carrier.
- a pharmaceutically acceptable carrier examples include excipients, coating agents, binders, extenders, disintegrants, surfactants, lubricants, diluents, dispersants, buffers, osmotic pressure adjusting agents, pH adjusting agents, Dispersants, emulsifiers, preservatives, stabilizers, antioxidants, colorants, UV absorbers, moisturizers, thickeners, activity enhancers, anti-inflammatory agents, bactericides, fragrances, flavoring agents, flavoring agents, etc. It is done.
- the said pharmaceutical and quasi-drug may contain another active ingredient and a pharmacological component, as long as the hair growth inhibitory action of a beech rose or its extract is not lost.
- the above-mentioned medicine or quasi-drug can be produced from common beech or extract thereof, or in combination with the above-mentioned carrier and / or other active ingredients and pharmacological ingredients as required.
- the content of beech grass or extract thereof in the medicine or quasi-drug is usually 0.001 to 99.999% by mass in terms of dry matter of the extract, and 0.01 to 20% by mass. preferable.
- the cosmetic contains beech rose or an extract thereof as an active ingredient.
- the cosmetic may contain beech grass or its extract alone, or may be contained in combination with a carrier acceptable as a cosmetic.
- carrier acceptable as a cosmetic examples include excipients, coating agents, binders, extenders, disintegrants, surfactants, lubricants, diluents, dispersants, buffers, osmotic pressure adjusting agents, pH adjusting agents, Dispersants, emulsifiers, preservatives, stabilizers, antioxidants, colorants, UV absorbers, moisturizers, thickeners, activity enhancers, anti-inflammatory agents, bactericides, fragrances, flavoring agents, flavoring agents, etc. It is done.
- the cosmetic is other active ingredients and cosmetic ingredients such as moisturizer, whitening agent, UV protection agent, cell activator, cleaning agent, It may contain keratolytic agents, makeup ingredients (for example, makeup bases, foundations, funny, powder, teak, lipstick, eye makeup, eyebrow, mascara, etc.).
- makeup ingredients for example, makeup bases, foundations, funny, powder, teak, lipstick, eye makeup, eyebrow, mascara, etc.
- cosmetic forms include creams, emulsions, lotions, suspensions, foams, gels, powders, packs, sheets, patches, sticks, cakes, and any other form that can be used for cosmetics.
- it may be in the form of a hair removal or hair removal lotion, emulsion, cream, foam, gel or the like.
- the above cosmetics can be produced from common beech or its extract, or in combination with the above carriers and / or other active ingredients and cosmetic ingredients as required.
- the content of beech rose or its extract in the cosmetic is usually 0.0001 to 99.999% by mass, preferably 0.001 to 10% by mass, in terms of dry matter of the extract.
- the above-mentioned food and drink or feed, or the raw materials thereof are intended and necessary for functions such as suppression of hair growth, suppression of hair growth or hair growth, or hair removal or hair removal, which contains beech grass or an extract thereof as an active ingredient.
- the food may be a food, a functional food, a food for a sick person, a food for specified health use, a pet food or the like, or a raw material thereof.
- the kind of said food / beverage products is not specifically limited.
- Examples of the beverage include all beverages such as fruit juice beverages, carbonated beverages, tea beverages, milk beverages, alcoholic beverages, and soft drinks.
- the form of the food may be any form such as solid, semi-solid, liquid, etc., and may be tablet form, pill form, tablet, capsule form, liquid form, syrup form, powder form, granule form, etc. Also good.
- food breads, noodles, pasta, jelly-like foods, various snacks, cakes, confectionery, ice creams, soups, dairy products, frozen foods, instant foods, other processed foods, seasonings, And supplements.
- the kind of the feed is not particularly limited, and may be a feed for any animal, and the form thereof may be any form as in the case of the food.
- the above-mentioned food and drink or feed, or their raw materials may contain beech grass or its extract alone, or other foods, solvents, softeners, oils, emulsifiers, preservatives, aromatics, stabilizers Further, additives such as a colorant, an antioxidant, a moisturizing agent, and a thickener may be contained in combination.
- the content of beech grass or its extract in the food or drink or feed is usually 0.0001 to 99.999% by mass, preferably 0.001 to 10% by mass, in terms of dry matter of the extract. .
- a method for inhibiting hair growth characterized by administering beech grass or an extract thereof.
- beech grass or an extract thereof is administered in an effective amount to a subject in need thereof for hair growth inhibition, hair growth or hair growth inhibition, hair removal or hair removal.
- beech grass or an extract thereof is taken in an effective amount by a subject in need thereof for hair growth inhibition, hair growth or hair growth inhibition, hair removal or hair removal.
- Subjects to be administered or ingested include animals, preferably humans or non-human mammals, more preferably humans.
- the subject to be administered or ingested can be an animal-derived tissue, organ, cell, or fraction thereof.
- the tissue, organ, cell, or fraction thereof is preferably a naturally-derived or biologically or bioengineered tissue, organ, cell, or fraction thereof having hair growth ability. is there.
- the tissue, organ, cell, or fraction thereof is derived from the skin.
- beech grass or its extract is applied to the above-listed areas where hair growth suppression is desired in the target skin tissue.
- Preferred dosages and intakes may vary according to the subject's species, weight, sex, age, condition or other factors.
- the dose, route, interval, and amount and interval of intake can be determined appropriately by those skilled in the art.
- the dosage when applied to human skin, is preferably 0.01 to 1000 mg / day, 0.1 to 100 mg / day per adult, as a beech extract (in terms of dried extract). Day is more preferred.
- each luciferase activity was measured.
- the luciferase assay was performed using the Dual-Glo Luciferase Assay System (Promega). After removing the medium, Dual-Glo luciferase reagent diluted 2-fold with PBS was added, and after stirring, the firefly luciferase activity was measured about 20 minutes later. Thereafter, an equal amount of Dual-Glo Stop & Glo reagent was added, and after stirring, Renilla luciferase activity was measured. In both cases, the measurement time for luciferase activity was 2 seconds.
- DnaJC6 promoter activity inhibition rate (%) ⁇ (Solvent control addition group-test substance addition group) / solvent control addition group ⁇ ⁇ 100
- RNA was extracted from MeWo cells cultured for 24 hours using RNeasy Mini Kit (QIAGEN). The preparation of total RNA was performed according to the attached instruction manual. The total RNA was subjected to heat treatment at 65 ° C. for 5 minutes after adjusting the concentration, and used after rapid cooling. For the reverse transcription reaction, a fixed amount of total RNA and Oligo (dT) 20 were used, and ThermoScript RT-PCR System (Invitrogen) was used. The reaction was performed according to the attached instruction manual. RT samples were stored at ⁇ 20 ° C. until use.
- Quantification of mRNA expression by Real-time RT-PCR was performed using a POWER SYBR-green PCR Master Mix (ABI) and a PCR product automatic detection / quantification system PRISM7500 (ABI).
- amplification conditions were 95 ° C., 15 seconds denaturation reaction, 60 ° C., 1 minute annealing and extension reaction.
- the expression level of DnaJC6 mRNA gene was corrected by the expression level of control gene RPLP0 mRNA.
- Primers used for RT-PCR were Primer express ver. Designed using 2.0 (ABI). The primers used are shown in Table 1 below.
- the primary antibodies were rabbit anti-DnaJC6 antibody prepared by standard methods at 1 ⁇ g / ml in 5% skim milk, and goat anti-beta-Actin (I-19) antibody (SantaCruz) in 0.2 ⁇ g in 5% skim milk. / Ml.
- Secondary antibodies were anti-rabbit IgG-HRP (Amersham) or anti-goat IgG-HRP (SantaCruz), respectively, and used at a dilution of 1/2000 in 5% skim milk.
- ECL color development was performed using LumiGLO Reagent and Peroxide (Cell Signaling) according to the instruction manual.
- Example 2 Evaluation of Barberation of Test Substance Using Human Isolated Hair Follicle A human scalp sample was disinfected by immersing in a 0.1% Hibiten solution for 1 minute and then washed with PBS. Thereafter, hair follicles were isolated using a forceps and a scalpel in a William E medium (Invitrogen) under a stereomicroscope.
- the isolated hair follicles were added to William E medium in 2 mM L-Glutamine (Invitrogen), 10 ⁇ g / ml Insulin (Invitrogen), 40 ng / ml Hydrocortisone (SIGMA), 1% Antibiotics-antimitogenics (Invitrogen) Medium (24 well plate, 300 ⁇ l) was cultured under conditions of 37 ° C. and 5% CO 2 .
- the oren extract and the beech rose extract prepared in Example 1 were adjusted to a concentration of 1 mg / ml with 50% ethanol and added to the medium so that the concentration was 0.1 vol% (final concentration 1 ⁇ g / ml).
- Example 2 Production Example Using the extract obtained in Example 1 as an active ingredient, lotions, creams, aerosols, packs, foundations, lotions, and gels having the compositions shown below were prepared by conventional methods.
- Aerosol The following component A was uniformly mixed and placed in a container, and the liquid petroleum gas (propellant) of B was filled into the container by a conventional method to produce an aerosol.
- Composition Composition: Mass%)
- a Funabara grass extract 1.0 (dry solids)
- Cetanol 1.2
- Propylene glycol 4.0
- Ethanol 8.0
- Purified water balance B Liquefied petroleum gas (propellant) 4.0
- composition Composition: Mass%) Beech grass extract 3.0 (dry solids) Polyvinyl alcohol 20.0 Glycerin 5.0 Ethanol 16.0 Fragrance Trace amount Pigment Trace amount Purified water Remaining
- composition Composition: Mass%) Beech extract (1.0% dry solids) Spherical silica beads 20.0 Silica coated sericite 45.0 Ultrafine titanium oxide 10.0 Yellow iron oxide 3.0 Talc 5.0 Mica 5.0 Bengala 1.0 Gunjo 1.0 Paraben 0.2 Liquid paraffin 4.8 Squalane 4.0
- composition Composition: Mass%) Beech extract (5.0% dry solids) Glycerin 15.0 Dipropylene glycol 5.0 Purified water balance
- composition Composition: Mass%) Polyacrylic acid 0.5 Potassium hydroxide 0.15 Gurucam 10.0 Glycerin 10.0 Glycine betaine 3.0 Beech extract (2.0 dry solids) Succinic acid 1.5 Purified water balance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Botany (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Zoology (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Abstract
Description
別の態様において、本発明は、下記工程(A)~(C):
(A)試験物質の存在下及び非存在下でDnaJC6を発現可能な細胞におけるDnaJC6の発現量を測定する工程;
(B)試験物質存在下での当該細胞におけるDnaJC6の発現量と、試験物質非存在下での当該細胞におけるDnaJC6の発現量とを比較する工程;及び
(C)試験物質の存在下と非存在下との間でDnaJC6の発現量が有意に異なっていた場合に、当該試験物質を毛成長制御剤として選択する工程、
を含む毛成長制御剤の評価又は選択方法を提供する。
本発明のまた別の態様は、毛成長抑制に使用するためのフナバラソウ又はその抽出物である。あるいは、毛成長抑制のための医薬若しくは化粧品の製造における、フナバラソウ又はその抽出物の使用である。
さらに別の態様において、本発明は、フナバラソウ又はその抽出物を毛成長抑制が所望される皮膚組織に適用することを含む毛成長抑制方法を提供する。
また別の態様において、本発明は、フナバラソウ又はその抽出物を有効成分として含有する毛成長抑制剤を提供する。
本明細書において、「DnaJC6遺伝子」、「DnaJC6 mRNA」、及び「DnaJC6プロモーター」とは、それぞれ、DnaJC6をコードする遺伝子、そのmRNA、及びDnaJC6をコードする遺伝子を制御するプロモーターをいう。
DnaJC6の活性化レベルを低下させる手段としては、例えば、DnaJC6タンパク質に特異的な抗体を用いたDnaJC6タンパク質の不活性化、DnaJC6遺伝子のプロモーターの活性を阻害することによるDnaJC6遺伝子からmRNAへの転写の抑制、RNAi等の手段によるDnaJC6 mRNAからタンパク質への翻訳の抑制等が挙げられる。
好ましい実施形態において、上記活性化レベルは、DnaJC6遺伝子のプロモーターの活性として好ましくは20%以上、より好ましくは50%以上低下する。あるいは、DnaJC6 mRNAの発現量として好ましくは10%以上、より好ましくは20%以上低下する。DnaJC6の活性化レベルの低下によって、上記組織の毛成長は抑制される。
DnaJC6の活性化レベルを増強させる手段としては、例えば、上記組織の細胞へのDnaJC6遺伝子の導入、上記組織の細胞へのDnaJC6遺伝子を含む発現ベクターの導入、DnaJC6遺伝子のプロモーターの活性を増加させることによるDnaJC6遺伝子からmRNAへの転写の促進、DnaJC6 mRNAの分解の抑制、DnaJC6タンパク質の分解の抑制等が挙げられる。
好ましい実施形態において、上記活性化レベルは、DnaJC6遺伝子のプロモーターの活性として好ましくは20%以上、より好ましくは50%以上増強する。あるいは、DnaJC6 mRNAの発現量として好ましくは10%以上、より好ましくは20%以上増強する。DnaJC6の活性化レベルの増強によって、上記組織の毛成長は促進される。
(A)試験物質の存在下及び非存在下でDnaJC6を発現可能な細胞におけるDnaJC6の発現量を測定する工程;
(B)試験物質存在下での当該細胞におけるDnaJC6の発現量と、試験物質非存在下での当該細胞におけるDnaJC6の発現量とを比較する工程;及び
(C)試験物質の存在下と非存在下との間でDnaJC6の発現量が有意に異なっていた場合に、当該試験物質を毛成長制御剤として選択する工程。
(a)DnaJC6をコードする遺伝子のプロモーターにより制御されるレポーター遺伝子を、DnaJC6を発現可能な細胞に導入する工程;
(b)試験物質の存在下及び非存在下で、当該細胞におけるレポーター遺伝子発現産物の量を測定する工程;
(c)試験物質存在下での当該細胞におけるレポーター遺伝子発現産物の量と、試験物質非存在下での当該細胞におけるレポーター遺伝子発現産物の量とを比較する工程;及び
(d)試験物質の存在下と非存在下との間で当該レポーター遺伝子発現産物の量が有意に異なっていた場合に、当該試験物質を毛成長制御剤として選択する工程。
測定に用いるプロモーターとしては、ヒトDnaJC6プロモーターが好ましい。ヒトDnaJC6プロモーターとしては、配列番号1で示される塩基配列を有するプロモーター、及び配列番号1で示される塩基配列に対して1個~数個(好ましくは1~10個、より好ましくは1~5個)の塩基が置換、欠失、挿入、付加されており、且つ配列番号1で示される塩基配列を有するプロモーターと同様の転写因子に制御されて下流の遺伝子の発現を制御するものが挙げられる。
斯かる担体としては、例えば、賦形剤、被膜剤、結合剤、増量剤、崩壊剤、界面活性剤、滑沢剤、希釈剤、分散剤、緩衝剤、浸透圧調整剤、pH調整剤、分散剤、乳化剤、防腐剤、安定剤、酸化防止剤、着色剤、紫外線吸収剤、保湿剤、増粘剤、活性増強剤、抗炎症剤、殺菌剤、香料、矯味剤、矯臭剤等が挙げられる。また、当該化粧料は、フナバラソウ又はその抽出物の毛成長抑制作用が失われない限り、他の有効成分や化粧成分、例えば、保湿剤、美白剤、紫外線保護剤、細胞賦活剤、洗浄剤、角質溶解剤、メークアップ成分(例えば、化粧下地、ファンデーション、おしろい、パウダー、チーク、口紅、アイメーク、アイブロウ、マスカラ、その他)等を含有していてもよい。
化粧料の形態としては、クリーム、乳液、ローション、懸濁液、フォーム、ジェル、パウダー、パック、シート、パッチ、スティック、ケーキ等、化粧料に使用され得る任意の形態が挙げられる。好ましくは、除毛又は脱毛用のローション、乳液、クリーム、フォーム、ジェル等の形態であり得る。
好ましくは、フナバラソウ又はその抽出物は、上記に挙げた対象の皮膚組織における毛成長抑制が所望される領域に適用される。
(1)手順
(A)オウレン抽出液の調製
オウレン根(新和物産)40gに50%エタノール水溶液400mLを加え、常温で13日間浸漬した。これをろ過し、オウレン抽出液を得た。このオウレン抽出液を濃縮したところ、その固形分は5.46gであった。抽出液の固形分濃度は1.73wt%であった。
(B)フナバラソウ抽出液の調製
フナバラソウ根(新和物産)40gに50%エタノール水溶液400mLを加え、常温で27日間浸漬した。これをろ過し、フナバラソウ抽出液を得た。このフナバラソウ抽出液を濃縮したところ、その固形分は4.39gであった。抽出液の固形分濃度は1.33wt%であった。
DnaJC6発現が認められるヒト培養細胞(293A、ATCCまたはMeWo、財団法人ヒューマンサイエンス振興財団)を、DMEM(Invitrogen、High glucose、10%heat-inactivated FBS)中37℃、5%CO2条件下で培養した。試験物質を50%エタノールにて1mg/mlの濃度に調製し、0.1vol%(最終濃度1μg/ml)となるように培地に添加した。対照群には、同量の50%エタノール溶液(Vehicle)を培地に添加した。
ヒトDnaJC6プロモーター(配列番号1:979bp[転写開始点から-771~+208])の下流にホタルルシフェラーゼ遺伝子が挿入されたhDnaJC6opP/pGL4.10[luc2]プラスミド、及びトランスフェクション効率の補正を目的としてCMV promoterの下流にウミシイタケルシフェラーゼが導入されたプラスミド(pRL-CMV、Promega)をLipofectAMINE2000 reagent(Invitrogen)を用いて、293A細胞にトランスフェクションした。その8時間後に培地を交換し、試験物質を添加した。更に24時間後にそれぞれのルシフェラーゼ活性を測定した。
ルシフェラーゼアッセイはDual-Glo Luciferase Assay System(Promega)を用いて行った。培地を除去後、PBSにより2倍希釈したDual-Glo luciferase reagentを加え、攪拌した後、約20分後にホタルルシフェラーゼ活性を測定した。その後、等量のDual-Glo Stop&Glo reagentを加え、攪拌した後にウミシイタケルシフェラーゼ活性を測定した。尚、双方ともルシフェラーゼ活性の測定時間は2秒とした。
全てのDnaJC6プロモーター活性(ホタルルシフェラーゼ活性)はトランスフェクション効率補正のために導入されたウミシイタケルシフェラーゼ活性にて除することで補正した。その後、DnaJC6プロモーター活性阻害率を以下の式にて求め、DnaJC6プロモーター活性を試験物質が何%阻害したかを算出した。
DnaJC6プロモーター活性阻害率(%)
={(溶媒対照添加群-試験物質添加群)/溶媒対照添加群}×100
試験物質を添加後、24時間培養したMeWo細胞からRNeasy Mini Kit(QIAGEN)を用いてtotal RNAを抽出した。total RNAの調製は付属の使用説明書に従って実施した。total RNAは濃度を揃えた後65℃、5分間の熱処理を行い、急冷後に使用した。逆転写反応には、一定量のtotal RNAとOligo(dT)20を用い、ThermoScript RT-PCR System(Invitrogen)を用い、反応は付属の使用説明書に従って実施した。RTサンプルは、使用まで-20℃で保存した。
Real-time RT-PCRによるmRNA発現の定量は、POWER SYBR-green PCR Master Mix(ABI)を用い、PCRプロダクト自動検出/定量システムPRISM7500(ABI)を用いて実施した。
50μlの反応液にて、増幅条件は、95℃、15秒の変性反応、60℃、1分のアニーリング及び伸長反応にて行った。DnaJC6 mRNA遺伝子発現量は、コントロール遺伝子RPLP0 mRNA発現量により補正した。RT-PCRに使用したプライマーはPrimer Express ver.2.0(ABI)を利用して設計した。用いたプライマーを以下の表1に示す。
試験物質を添加後、24時間培養したMeWo細胞を回収後、1% protease inhibitor cocktail(SIGMA)を含むLysis buffer(50mM Tris-HCl、125mM NaCl、0.5% NP40、pH=7.6)により可溶化し、Sample bufferと混合後、100℃、5分間熱処理した後にウェスタンブロッティングに用いた。ポリアクリルアミドゲル電気泳動は標準的な方法で行い、4-20% gradient gelを用いた。ブロッティングはウェット法によりHybond P(Amersham)メンブレンに転写した。メンブレンに転写後、5%スキムミルクでブロッキングを行った。一次抗体は、標準的な方法にて作製したrabbit anti-DnaJC6抗体を5%スキムミルク中1μg/mlで、goat anti-beta-Actin(I-19)抗体(SantaCruz)を5%スキムミルク中0.2μg/mlで使用した。二次抗体は、それぞれanti-rabbit IgG-HRP(Amersham)またはanti-goat IgG-HRP(SantaCruz)を用い、5%スキムミルク中1/2000希釈で使用した。ECL発色はLumiGLO Reagent and Peroxide(Cell Signaling)を用い、使用説明書に従って行った。
結果を図1、2及び3に示す。対照群(Vehicle)に対してオウレン及びフナバラソウエキスを添加した群では、それぞれDnaJC6プロモーター活性及びDnaJC6 mRNA発現が有意に抑制され、DnaJC6タンパク質発現量も抑制された。
ヒト頭皮サンプルは0.1%ヒビテン液に1分間浸漬して消毒後、PBSにて洗浄した。その後、William E培地(Invitrogen)中、実体顕微鏡下にてピンセットとメスを用いて毛包を単離した。単離した毛包は、William E培地に2mM L-Glutamine(Invitrogen)、10μg/ml Insulin(Invitrogen)、40ng/ml Hydrocortisone(SIGMA)、1% Antibiotics-antimitotics(Invitrogen)となるように添加した培地中(24well plate、300μl)にて37℃、5% CO2条件下で培養した。実施例1で調製したオウレン抽出液とフナバラソウ抽出液を50%エタノールにて1mg/mlの濃度に調製し、0.1vol%(最終濃度1μg/ml)となるように培地に添加した。対照として、同量の50%エタノール溶液(Vehicle)を培地に添加した。
器官培養毛は、経時的に顕微鏡下で写真を撮影、同条件で撮影されたスケールを元に画像解析にて毛包の長さを算出した。画像解析はNewQube(version 4.0.3、Nexus)により実施し、初期値からの増加量を毛伸長量とした。
実施例1で得られた抽出物を有効成分として、下記に示す組成のローション、クリーム、エアゾール、パック剤、ファンデーション、化粧水、ジェルを常法により各々調製した。
下記Aの成分を混合した溶液Aを調製した。これとは別に、下記Bの成分を混合した溶液Bを調製した。溶液Aに溶液Bを添加して均一に撹拌混合し、ローションを得た。
(組成) (配合:質量%)
A ポリオキシエチレン硬化ひまし油 0.8
エタノール 30.0
B フナバラソウ抽出物 1.0(乾燥固形分)
ドデシル硫酸ナトリウム 0.12
ドデシルメチルアミンオキシド 0.18
イソプロピルアルコール 15.0
ベンジルアルコール 15.0
グリセリン 2.0
精製水 残部
下記Aの成分を混合した溶液Aを調製した。これとは別に、下記Bの成分を混合した溶液Bを調製した。溶液Aに溶液Bを添加して均一に撹拌混合し、乳化後、冷却して、クリームを得た。
(組成) (配合:質量%)
A 流動パラフィン 10.0
スクワラン 7.0
ホホバ油 3.0
固形パラフィン 3.0
ポリオキシエチレンセチルエーテル 2.0
ソルビタンセスキオレエート 1.0
水酸化カリウム 0.1
B フナバラソウ抽出物 1.0(乾燥固形分)
グリセリン 3.0
エチルパラベン 0.1
精製水 残部
下記Aの成分を均一に混合して容器に入れ、Bの液化石油ガス(噴射剤)を常法により容器に充填してエアゾールを製造した。
(組成) (配合:質量%)
A フナバラソウ抽出物 1.0(乾燥固形分)
セタノール 1.2
プロピレングリコール 4.0
エタノール 8.0
精製水 残部
B 液化石油ガス(噴射剤) 4.0
下記の組成のパック剤を常法により調製した。
(組成) (配合:質量%)
フナバラソウ抽出物 3.0(乾燥固形分)
ポリビニルアルコール 20.0
グリセリン 5.0
エタノール 16.0
香料 微量
色素 微量
精製水 残部
下記の組成のファンデーションを常法により調製した。
(組成) (配合:質量%)
フナバラソウ抽出物 1.0(乾燥固形分)
球状シリカビーズ 20.0
シリカ被覆セリサイト 45.0
超微粒子酸化チタン 10.0
黄酸化鉄 3.0
タルク 5.0
マイカ 5.0
ベンガラ 1.0
グンジョウ 1.0
パラベン 0.2
流動パラフィン 4.8
スクワラン 4.0
下記の組成の化粧水を常法により調製した。
(組成) (配合:質量%)
フナバラソウ抽出物 5.0(乾燥固形分)
グリセリン 15.0
ジプロピレングリコール 5.0
精製水 残部
下記の組成のジェルを常法により調製した。
(組成) (配合:質量%)
ポリアクリル酸 0.5
水酸化カリウム 0.15
グルカム 10.0
グリセリン 10.0
グリシンベタイン 3.0
フナバラソウ抽出物 2.0(乾燥固形分)
コハク酸 1.5
精製水 残部
Claims (21)
- 毛包組織におけるDnaJC6の活性化レベルを制御する工程を含む、毛成長制御方法。
- 前記制御する工程が、DnaJC6の活性化レベルを低下させることによって毛成長を抑制する工程である、請求項1記載の方法。
- 前記制御する工程が、DnaJC6の活性化レベルを増強させることによって毛成長を促進する工程である、請求項1記載の方法。
- 前記制御する工程が、DnaJC6タンパク質の存在量、DnaJC6タンパク質の活性化、DnaJC6タンパク質の発現、DnaJC6タンパク質をコードする遺伝子若しくはmRNAの発現、又はDnaJC6タンパク質をコードする遺伝子のプロモーターの活性化を制御する工程である、請求項1記載の方法。
- 前記組織がヒト毛包組織である、請求項1記載の方法。
- 下記工程(A)~(C):
(A)試験物質の存在下及び非存在下でDnaJC6を発現可能な細胞におけるDnaJC6の発現量を測定する工程;
(B)試験物質存在下での当該細胞におけるDnaJC6の発現量と、試験物質非存在下での当該細胞におけるDnaJC6の発現量とを比較する工程;及び
(C)試験物質の存在下と非存在下との間でDnaJC6の発現量が有意に異なっていた場合に、当該試験物質を毛成長制御剤として選択する工程、
を含む毛成長制御剤の評価又は選択方法。 - 前記(C)において、DnaJC6の発現量を減少させる前記試験物質は毛成長抑制剤として選択され、DnaJC6の発現量を増加させる前記試験物質は毛成長促進剤として選択される、請求項6記載の方法。
- 前記DnaJC6の発現量が、DnaJC6タンパク質の発現、DnaJC6タンパク質をコードする遺伝子若しくはmRNAの発現、又はDnaJC6タンパク質をコードする遺伝子のプロモーターの活性化の量である、請求項6又は7記載の方法。
- DnaJC6タンパク質をコードする遺伝子若しくはmRNAの発現量の測定が、ポリメラーゼ連鎖反応(PCR)法、又はNorthern blotting法、又はRNase protection assay法、又はDNAアレイ解析により行われる、請求項8記載の方法。
- DnaJC6のタンパク質の発現量の測定が、DnaJC6タンパク質に特異的な抗体を利用するWestern blotting法、ELISA法、又はRIA法により行われる、請求項8記載の方法。
- 前記DnaJC6の発現量がDnaJC6タンパク質をコードする遺伝子のプロモーターにより制御されるレポーター遺伝子の発現産物の量であり、前記(A)において、前記DnaJC6を発現可能な細胞に当該レポーター遺伝子を予め導入する工程を含む請求項6記載の方法。
- 前記レポーター遺伝子発現産物の量を減少させる前記試験物質は毛成長抑制剤として選択され、該レポーター遺伝子発現産物の量を増加させる前記試験物質は毛成長促進剤として選択される、請求項11記載の方法。
- 前記レポーター遺伝子が、ルシフェラーゼ、クロラムフェニコールアセチルトランスフェラーゼ、β-ガラクトシダーゼ、β-グルクロニダーゼ、及び緑色蛍光タンパク質からなる群より選択される、請求項11記載の方法。
- 前記DnaJC6を発現可能な細胞が、哺乳動物皮膚由来の切片、培養細胞又は高次皮膚培養物中に存在する細胞である請求項6又は11に記載の方法。
- 毛成長の抑制に使用するためのフナバラソウ又はその抽出物。
- 抽出物が水抽出物又はエタノール水溶液抽出物である請求項15記載の抽出物。
- 毛成長抑制のための医薬若しくは化粧品の製造におけるフナバラソウ又はその抽出物の使用。
- 抽出物が水抽出物又はエタノール水溶液抽出物である請求項17記載の使用。
- エタノール水溶液が40~60容量%エタノール水溶液である請求項17記載の使用。
- フナバラソウ又はその抽出物を毛成長抑制が所望される皮膚組織に適用することを含む毛成長抑制方法。
- 抽出物が水抽出物又はエタノール水溶液抽出物である請求項20記載の方法。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/821,380 US9005898B2 (en) | 2010-09-09 | 2011-09-08 | Method for controlling hair growth, method for selecting or evaluating hair growth control agent, and hair growth suppression agent |
EP11823636.3A EP2614813B1 (en) | 2010-09-09 | 2011-09-08 | Method for selecting or evaluating hair growth control agent |
CN201180043505.0A CN103118661B (zh) | 2010-09-09 | 2011-09-08 | 毛发生长控制方法、毛发生长控制剂的评价或选择方法、以及毛发生长抑制剂 |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-201838 | 2010-09-09 | ||
JP2010201837A JP5537352B2 (ja) | 2010-09-09 | 2010-09-09 | 毛成長抑制剤 |
JP2010-201837 | 2010-09-09 | ||
JP2010201838A JP5654808B2 (ja) | 2010-09-09 | 2010-09-09 | 毛成長制御剤の評価又は選択方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012033162A1 true WO2012033162A1 (ja) | 2012-03-15 |
Family
ID=45810758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/070481 WO2012033162A1 (ja) | 2010-09-09 | 2011-09-08 | 毛成長制御方法、毛成長制御剤の評価又は選択方法、及び毛成長抑制剤 |
Country Status (4)
Country | Link |
---|---|
US (1) | US9005898B2 (ja) |
EP (1) | EP2614813B1 (ja) |
CN (1) | CN103118661B (ja) |
WO (1) | WO2012033162A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016514969A (ja) * | 2013-03-19 | 2016-05-26 | ザ プロクター アンド ギャンブル カンパニー | 毛包の代謝指標を測定する方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107308451A (zh) * | 2017-06-08 | 2017-11-03 | 深圳培元生物科技有限公司 | 一种毛发生长抑制剂及其用途 |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1149647A (ja) | 1997-07-31 | 1999-02-23 | Shiseido Co Ltd | 毛髪成長期延長剤のスクリーニング方法 |
JP2002062289A (ja) | 2000-08-24 | 2002-02-28 | Toagosei Co Ltd | 毛球部活性化剤および毛髪成長期間延長剤のスクリーニング方法 |
JP2003221313A (ja) | 2002-01-25 | 2003-08-05 | Kunio Tsuji | 津液作用を有する生薬のエキス及び血管新生活性を有する生薬エキスからなる育毛用の皮膚外用剤 |
JP2003221315A (ja) * | 2002-01-25 | 2003-08-05 | Kunio Tsuji | 育毛用の皮膚外用剤 |
WO2003086331A2 (en) | 2002-04-11 | 2003-10-23 | The Gillette Company | Reduction of hair growth |
CN1562259A (zh) * | 2004-04-05 | 2005-01-12 | 傅京亮 | 益寿药香枕 |
JP2005206536A (ja) | 2004-01-23 | 2005-08-04 | Kao Corp | 育毛剤組成物 |
JP2006008657A (ja) | 2004-05-26 | 2006-01-12 | Motohide Takahama | 発毛抑制剤 |
WO2006124836A1 (en) * | 2005-05-13 | 2006-11-23 | Duke University | Gene expression signatures for oncogenic pathway deregulation |
WO2007020755A1 (ja) * | 2005-08-12 | 2007-02-22 | Kenji Kohno | 育毛剤 |
JP2007517824A (ja) | 2004-01-16 | 2007-07-05 | コグニス・フランス・ソシエテ・パール・アクシオン・サンプリフィエ | ガガイモ科植物の抽出物の使用 |
JP2008255078A (ja) * | 2007-04-09 | 2008-10-23 | Noevir Co Ltd | 保湿剤、抗老化剤、美白剤、抗酸化剤、痩身剤、トリートメント剤、アルギナーゼ活性促進剤及び皮膚外用剤 |
JP4189024B2 (ja) | 2004-04-27 | 2008-12-03 | ザ ジレット コンパニー | 育毛低減のための熱ショックタンパク質阻害物質の使用 |
WO2010016606A2 (en) | 2008-08-05 | 2010-02-11 | Kao Corporation | Hair growth regulating agent |
US20110059917A1 (en) * | 2009-08-14 | 2011-03-10 | Joaquin Jimenez | Vitamin d3 and analogs thereof for treating alopecia |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1352637B1 (en) * | 2000-12-22 | 2009-07-01 | Shiseido Company, Ltd. | Hair growth inhibitors and compositions containing the same |
WO2007140390A2 (en) * | 2006-05-31 | 2007-12-06 | The Rockefeller University | Method for modulating hair growth |
JP5654808B2 (ja) * | 2010-09-09 | 2015-01-14 | 花王株式会社 | 毛成長制御剤の評価又は選択方法 |
JP5537352B2 (ja) * | 2010-09-09 | 2014-07-02 | 花王株式会社 | 毛成長抑制剤 |
JP5658575B2 (ja) * | 2011-01-27 | 2015-01-28 | 花王株式会社 | 毛成長抑制剤 |
JP2012153660A (ja) * | 2011-01-27 | 2012-08-16 | Kao Corp | DnaJC6発現抑制剤 |
-
2011
- 2011-09-08 WO PCT/JP2011/070481 patent/WO2012033162A1/ja active Application Filing
- 2011-09-08 CN CN201180043505.0A patent/CN103118661B/zh not_active Expired - Fee Related
- 2011-09-08 US US13/821,380 patent/US9005898B2/en not_active Expired - Fee Related
- 2011-09-08 EP EP11823636.3A patent/EP2614813B1/en not_active Not-in-force
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1149647A (ja) | 1997-07-31 | 1999-02-23 | Shiseido Co Ltd | 毛髪成長期延長剤のスクリーニング方法 |
JP2002062289A (ja) | 2000-08-24 | 2002-02-28 | Toagosei Co Ltd | 毛球部活性化剤および毛髪成長期間延長剤のスクリーニング方法 |
JP2003221313A (ja) | 2002-01-25 | 2003-08-05 | Kunio Tsuji | 津液作用を有する生薬のエキス及び血管新生活性を有する生薬エキスからなる育毛用の皮膚外用剤 |
JP2003221315A (ja) * | 2002-01-25 | 2003-08-05 | Kunio Tsuji | 育毛用の皮膚外用剤 |
WO2003086331A2 (en) | 2002-04-11 | 2003-10-23 | The Gillette Company | Reduction of hair growth |
JP2007517824A (ja) | 2004-01-16 | 2007-07-05 | コグニス・フランス・ソシエテ・パール・アクシオン・サンプリフィエ | ガガイモ科植物の抽出物の使用 |
JP2005206536A (ja) | 2004-01-23 | 2005-08-04 | Kao Corp | 育毛剤組成物 |
CN1562259A (zh) * | 2004-04-05 | 2005-01-12 | 傅京亮 | 益寿药香枕 |
JP4189024B2 (ja) | 2004-04-27 | 2008-12-03 | ザ ジレット コンパニー | 育毛低減のための熱ショックタンパク質阻害物質の使用 |
JP2006008657A (ja) | 2004-05-26 | 2006-01-12 | Motohide Takahama | 発毛抑制剤 |
WO2006124836A1 (en) * | 2005-05-13 | 2006-11-23 | Duke University | Gene expression signatures for oncogenic pathway deregulation |
WO2007020755A1 (ja) * | 2005-08-12 | 2007-02-22 | Kenji Kohno | 育毛剤 |
JP2008255078A (ja) * | 2007-04-09 | 2008-10-23 | Noevir Co Ltd | 保湿剤、抗老化剤、美白剤、抗酸化剤、痩身剤、トリートメント剤、アルギナーゼ活性促進剤及び皮膚外用剤 |
WO2010016606A2 (en) | 2008-08-05 | 2010-02-11 | Kao Corporation | Hair growth regulating agent |
US20110059917A1 (en) * | 2009-08-14 | 2011-03-10 | Joaquin Jimenez | Vitamin d3 and analogs thereof for treating alopecia |
Non-Patent Citations (4)
Title |
---|
JINDO ET AL., THE JOURNAL OF DERMATOLOGY, vol. 20, 1993, pages 756 - 762 |
MAKOTO UZUKA; CHIKA HANZAWA, THE JAPANESE JOURNAL OF DERMATOLOGY, vol. 104, no. 8, 1994, pages 979 - 987 |
PHILPOTT ET AL., JOURNAL OF CELL SCIENCE, vol. 97, 1990, pages 463 - 471 |
See also references of EP2614813A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016514969A (ja) * | 2013-03-19 | 2016-05-26 | ザ プロクター アンド ギャンブル カンパニー | 毛包の代謝指標を測定する方法 |
Also Published As
Publication number | Publication date |
---|---|
EP2614813A4 (en) | 2015-12-02 |
EP2614813B1 (en) | 2017-03-15 |
CN103118661A (zh) | 2013-05-22 |
US20130216632A1 (en) | 2013-08-22 |
CN103118661B (zh) | 2017-09-22 |
EP2614813A1 (en) | 2013-07-17 |
US9005898B2 (en) | 2015-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6145106B2 (ja) | 精製したセコイリドイドグルコシド誘導体からなる発毛促進剤、IGF−1発現増加剤、VEGF発現増加剤、HGF発現増加剤、KGF発現増加剤、およびβ−カテニン発現増加剤 | |
TWI747280B (zh) | 余甘子萃取發酵物及其製備與應用 | |
JP5990058B2 (ja) | エストロゲン受容体β活性化剤 | |
KR101733065B1 (ko) | 데칸알 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 조성물 | |
WO2012033162A1 (ja) | 毛成長制御方法、毛成長制御剤の評価又は選択方法、及び毛成長抑制剤 | |
JP2013193985A (ja) | 育毛剤 | |
JP5819209B2 (ja) | 幹細胞から褐色脂肪細胞への分化促進剤 | |
KR20190000609A (ko) | 세스퀴테르펜 유도체를 유효성분으로 함유하는 근력강화, 근육증강, 근육분화, 근육재생 또는 근감소증 억제효과를 갖는 조성물 | |
KR101841118B1 (ko) | 세네데스무스 속 미세조류의 추출물을 유효성분으로 함유하는 피부 외용제 조성물 | |
JP5537352B2 (ja) | 毛成長抑制剤 | |
JP2011102264A (ja) | アロマターゼ活性化剤 | |
KR102034436B1 (ko) | 베트남 후피향 추출물을 포함하는 아토피 피부염 치료 및 예방용 조성물 | |
JP5658575B2 (ja) | 毛成長抑制剤 | |
KR20190067700A (ko) | 흑초 및 나이아신아마이드를 포함하는 여드름 개선용 화장료 조성물 | |
JP2015178471A (ja) | インボルクリン発現抑制剤 | |
JP5654808B2 (ja) | 毛成長制御剤の評価又は選択方法 | |
JP2014015428A (ja) | サテライト細胞分化促進剤 | |
CN112823156B (zh) | 具有抑制tslp分泌能力的松萝酸衍生物及其用途 | |
JP6002510B2 (ja) | エストロゲン受容体β活性化剤 | |
JP2012153660A (ja) | DnaJC6発現抑制剤 | |
JP7455344B2 (ja) | Endo180産生促進剤 | |
JP2022096767A (ja) | Tiparp産生促進剤 | |
JP2017079675A (ja) | 終末糖化産物産生抑制剤、並びに、これを含む食品、飲料及び化粧品 | |
WO2020230331A1 (ja) | Apj発現促進剤 | |
JP2021143137A (ja) | 育毛及び/又は発毛用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180043505.0 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11823636 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2011823636 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011823636 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13821380 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |